약물 스크리닝 세계 시장 규모는 2024년 68억 7,000만 달러에 달했습니다. 향후 2033년에는 120억 3,000만 달러에 달하고, 2025-2033년 6.37%의 연평균 복합 성장률(CAGR)을 보일 것으로 추정됩니다. 현재 시장을 독점하고 있는 것은 북미가며, 2024년 시장 점유율은 51%를 초과할 것입니다. 북미의 성장 원동력은 엄격한 작업장 규제, 첨단 검사 기술, 약물 남용에 대한 인식 증가입니다.
주요 시장 성장 촉진요인 : 약물 검사는 정확하고 자발적인 결과를 얻을 수 있기 때문에 수요가 증가하고 있으며, 이는 주로 시장 성장의 원동력이 되고 있습니다. 또한, 전 세계적으로 약물 남용 사례가 증가하고 있는 것도 세계 시장을 촉진하고 있습니다.
주요 시장 동향 : 자동화, 인공지능(AI), 분자진단 등 첨단 기술을 약물 스크리닝 검사에 통합하여 워크플로우를 간소화하고, 인적 오류를 줄이고, 검사를 강화하는 것이 중요한 주요 트렌드 중 하나로 작용하여 시장 성장을 견인하고 있습니다.
경쟁 환경: 약물 스크리닝 시장의 주요 기업으로는 Abbott Laboratories,Alfa Scientific Designs Inc. Corporation of America Holdings,Lifeloc Technologies Inc. Diagnostics Incorporated, Siemens AG, Thermo Fisher Scientific Inc. 등이 있습니다.
지리적 동향 : 보고서에 따르면, 북미는 약물 검사의 가장 큰 시장입니다. 이 지역의 성장은 약물 남용의 심각성, 마약 딜러 증가, 처방약의 암거래 증가에 기인합니다.
과제와 기회: 약물 스크리닝 시장은 정확하고 신뢰할 수 있는 검사 개발, 위양성 및 위음성 극복, 시료 채취 및 검사 절차에 대한 프라이버시 및 윤리적 우려에 대한 대응과 관련된 장애물에 직면해 있습니다. 비즈니스 기회는 데이터 분석을 위한 AI 및 머신러닝과 같은 첨단 기술의 통합과 편리하고 신속한 스크리닝을 위한 휴대용 및 현장 검사 기기의 개발에서 찾을 수 있습니다.
약물 및 알코올 소비 증가
약물 소비 증가로 인해 약물 스크리닝 제품에 대한 수요가 증가하고 있습니다. 예를 들어, 2023 European Drug Report에 따르면, 유럽연합(EU) 성인의 약 8,340만 명(29%)이 한 번이라도 불법 약물을 사용한 적이 있는 것으로 보고되었습니다. 대마초는 유럽에서 소비되는 주요 불법 약물이며, 각국의 조사에 따르면 2022년에는 유럽 성인의 8%가 대마초를 사용할 것으로 추정됩니다. 이처럼 많은 인구가 약물을 소비하고 있기 때문에 개인의 삶에 영향을 미치고 약물 검사에 대한 수요가 증가하고 약물 검사 시장의 최근 가격을 높일 가능성이 높습니다. 또한, 약물 및 알코올 사용 증가와 치료의 필요성이 증가함에 따라 병원에서의 약물 검사에 대한 수요가 증가할 것으로 예측됩니다. 예를 들어, GOV.UK가 발표 한 국가 통계에 따르면 2023년12 월에 병원에서 약물 검사에 대한 수요가 증가할 것으로 예상되며, 영국이 발표 한 국가 통계에 따르면 2023년12 월, 2022년4 월부터 2023년3 월까지 약 29,635 명의 성인이 약물 사용 문제로 도움을 받았다고합니다. 을 받았습니다. 이는 전년도 약 28만 9,215명에 비해 소폭 증가한 수치입니다. 또한 같은 자료에 따르면 2022년부터 2023년까지 치료를 받은 성인은 약 13만 7,749명으로 지난 2년간 13만 490명, 13만 3,704명보다 더 많은 것으로 나타났습니다. 이러한 물질 사용 중인 사람들의 대폭적인 증가는 약물 스크리닝 시장 수요를 촉진할 것으로 예측됩니다.
정부 규제
다양한 분야에서 약물 및 알코올 검사를 의무화하는 여러 법률 및 규정이 있으며, 이러한 법률의 시행으로 인해 약물 검사 제품 및 장비에 대한 수요가 증가하고 있습니다. 예를 들어, 2022년 11월 미국 연방교통안전국(FMCSA)은 약물 및 알코올 검사 요건을 요약한 업데이트를 발표했습니다. 이 규정은 검사 대상자, 검사 빈도, 검사 발단 상황 등을 규정하고 있습니다. 또한, 고용주 및 서비스 기관이 약물 및 알코올 검사에 대한 기밀 정보를 사용하거나 공개하는 것을 제한하여 직원의 프라이버시를 보호하고 있습니다. 규제 프레임워크 외에도 각국 정부 당국은 심각한 중독자 및 약물 남용으로 고통받는 사람들을 지원하기 위한 이니셔티브를 취하고 있으며, 이는 약물 검사 시장 점유율을 더욱 높이고 있습니다. 예를 들어, Nasha Mukt Bharat Abhiyaan은 인도 정부의 프로그램으로 대중에게 다가서고 인식 개선 프로그램과 같은 다양한 활동을 통해 약물 남용에 대한 인식을 확산시키는 것을 목적으로 합니다. 마찬가지로 캐나다 정부 당국도 마약 중독자들이 약물 남용에서 벗어날 수 있도록 마약 퇴치 프로젝트에 투자하고 있습니다. 예를 들어, 캐나다 앨버타 주에 위치한 캘거리 존 하워드 협회는 약물 중독으로 인해 학교 중퇴 위기에 처한 13세에서 24세 사이의 청소년을 지원하는 데 주력하고 있습니다.
검사 기술의 발전
신속 검사 키트, 실험실 기반 분석, 현장 진단 기기 등 약물 스크리닝 기술의 지속적인 발전은 보다 신속하고 정확하며 비용 효율적인 스크리닝 솔루션을 제공함으로써 시장 성장을 더욱 촉진하고 있습니다. 또한, 약물 스크리닝 기술의 지속적인 개선으로 정확성과 신뢰성이 향상되고 위양성 및 위음성의 가능성이 감소하여 검사 결과에 대한 신뢰성을 보장하고, 확인 검사의 필요성을 최소화하고, 스크리닝 프로세스를 간소화하며, 비용을 절감하고 있습니다. 예를 들어, 2024년 2월 모바일 헬스(Mobile Health)는 뉴욕의 한 클리닉에서 고용주가 후보자를 쉽게 선별하고 채용할 수 있는 새로운 신속 약물 검사 서비스를 도입했습니다. 마찬가지로 2023년 10월 ProciseDx Inc.는 아달리무맙(휴미라 및 바이오시밀러 Amgevita)과 인플릭시맙(레미케이드 및 바이오시밀러 Inflectra 및 Renflexis)에 대한 치료 약물 모니터링(TDM) 검사에 대한 새로운 FDA 허가를 획득했습니다. Procise ADL 및 Procise IFX라고 불리는 이 분석은 이들 약물을 복용 중인 염증성 장질환(IBD) 환자에서 아달리무맙(ADL) 및 인플릭시맙(IFX)을 정량화하는 데 사용됩니다. 새로운 약물 검사 및 기기의 승인 증가는 향후 몇 년 동안 약물 스크리닝 시장의 수익을 촉진할 것으로 예측됩니다.
The global drug screening market size was valued at USD 6.87 Billion in 2024. Looking forward, it is estimated that the market to reach USD 12.03 Billion by 2033, exhibiting a CAGR of 6.37% from 2025-2033. North America currently dominates the market, holding a market share of over 51% in 2024. The growth of the North American region is driven by stringent workplace regulations, advanced testing technologies, and increased substance abuse awareness.
Major Market Drivers: Increasing demand for drug screening as it is accurate and provides spontaneous results is primarily driving the growth of the market. Furthermore, the rising cases of substance abuse around the world are also propelling the global market.
Key Market Trends: The integration of advanced technologies such as automation, artificial intelligence (AI), and molecular diagnostics with drug screening tests to streamline workflows, reduce human errors, and enhance testing is acting as one of the significant key trends, bolstering the market growth.
Competitive Landscape: Some of the leading drug screening market companies include Abbott Laboratories, Alfa Scientific Designs Inc., Bio-Rad Laboratories Inc., Dragerwerk AG & Co. KGaA, Laboratory Corporation of America Holdings, Lifeloc Technologies Inc., Omega Laboratories Inc., OraSure Technologies Inc., Psychemedics Corporation, Quest Diagnostics Incorporated, Siemens AG, and Thermo Fisher Scientific Inc., among others.
Geographical Trends: According to the report, North America is the largest market for drug screening. The growth of the region can be attributed to the escalating cases of substance abuse, the increasing number of drug dealers, and the rising black marketing of prescribed drugs.
Challenges and Opportunities: The drug screening market faces hurdles related to the development of accurate and reliable tests, overcoming false positives and negatives, and addressing privacy and ethical concerns regarding sample collection and testing procedures. Opportunities lie in the integration of advanced technologies such as AI and machine learning for data analysis and the development of portable and point-of-care testing devices for convenient and rapid screening applications.
Rise in Drug and Alcohol Consumption
The increasing consumption of drugs is resulting in an increased demand for drug-screening products. For instance, according to the 2023 European Drug Report, approximately 83.4 million adults (29%) in the European Union have reportedly used illicit drugs at least once. Cannabis is the predominant illicit drug consumed in Europe, with an estimated 8% of European adults using it in 2022, based on national surveys. Thus, a high number of the population consumes drugs, which impacts the lives of individuals and is likely to increase demand for drug screening, thereby bolstering the drug screening market's recent price. Additionally, the rising utilization of drugs and alcohol, along with the need for treatment, is anticipated to drive up the demand for drug screening in hospitals. For instance, as per National statistics published by GOV. UK, in December 2023, between April 2022 and March 2023, around 290,635 adults received support for substance use issues. This is a small rise compared to the previous year, around 289,215. Moreover, the same source stated that the number of adults entering treatment from 2022 to 2023 was approx. 137,749, which is higher than the previous two years' figures of 130,490 and 133,704. Such a significant rise in the number of people undergoing substance use is anticipated to propel the drug screening market demand.
Government Regulations
Several laws and regulations mandate drug and alcohol testing in various sectors, and the implementation of such laws is augmenting the demand for drug-screening products and devices. For instance, in November 2022, the Federal Motor Carrier Safety Administration (FMCSA) released updates outlining the drug and alcohol testing requirements. These regulations specify the individuals subject to testing, the frequency of testing, and the circumstances triggering testing. Additionally, the regulations safeguard employee privacy by limiting the use and disclosure of sensitive drug and alcohol testing information by employers and service agents. Besides the regulatory framework, government authorities of various nations are also taking initiatives to help severe addicts and individuals suffering from drug abuse, which is further propelling the drug screening market share. For instance, Nasha Mukt Bharat Abhiyaan is a program by the Indian Government that intends to reach out to the masses and spread awareness about substance abuse through various activities like awareness generation programs. Similarly, the government authorities of Canada are also investing in anti-drug strategy projects to help people with addiction come out of substance abuse. For example, the Calgary John Howard Society in Alberta, Canada, focuses on assisting youths aged 13 to 24 who face the risk of school dropout due to drug addiction.
Advancements in Testing Technologies
Ongoing advancements in drug screening technologies, such as rapid testing kits, laboratory-based assays, and point-of-care devices, are further driving the market growth by offering faster, more accurate, and cost-effective screening solutions. Moreover, the continuous improvement of drug screening technologies is resulting in enhanced accuracy and reliability and reduced likelihood of false positives or false negatives, ensuring confidence in test results and minimizing the need for confirmatory testing, thereby streamlining the screening process and reducing costs. For instance, in February 2024, Mobile Health introduced a new rapid drug testing service in New York clinics for employers to screen and hire candidates easily. Similarly, in October 2023, ProciseDx Inc. received de novo FDA clearance for the therapeutic drug monitoring (TDM) tests for adalimumab (Humira and biosimilar Amgevita) and infliximab (Remicade and biosimilars Inflectra and Renflexis). These assays, called Procise ADL and Procise IFX, are used to quantify adalimumab (ADL) and infliximab (IFX) in patients suffering from inflammatory bowel diseases (IBD) who are taking these drugs. Increasing approval of new drug tests and instruments is anticipated to propel the drug screening market revenue in the coming years.
Rapid testing devices represented the largest segment
The drug screening market report has provided a detailed breakup and analysis of the drug screening market based on the product and service. This includes equipment (immunoassay analyzers, chromatography instruments, and breath analyzers); rapid testing devices (urine testing devices and oral fluid testing devices); consumables (assay kits, sample collection cups, calibrators and controls, and others); and laboratory services. According to the report, rapid testing devices (urine testing devices and oral fluid testing devices) represented the largest segment.
Rapid drug screening test devices are portable, easy-to-use tools designed for quick detection of drugs in various sample types, such as urine, saliva, or blood. These devices offer several benefits, including rapid results within minutes, enabling on-the-spot decision-making in scenarios like workplace testing or roadside screening. Their simplicity allows for minimal training requirements, making them accessible to a wide range of users. Moreover, rapid tests are cost-effective, reducing the need for laboratory analysis and turnaround time. For instance, Drager, a German company based in Lubeck that makes breathing and protection equipment, gas detection and analysis systems, and non-invasive patient monitoring technologies, introduced a rapid test named DrugTest 5000. In this test, saliva samples can be analyzed immediately for an accurate result on the spot. Furthermore, rapid screening devices play a crucial role in emergencies, aiding in the quick identification of drug intoxication or overdose for prompt medical intervention.
Urine samples accounted for the largest market share
As per the drug screening market overview, urine sample drug testing offers several benefits, making it a preferred method over other sample types in many scenarios. Firstly, urine testing is non-invasive and relatively easy to collect, minimizing discomfort and ensuring employee cooperation. Secondly, urine samples can detect a wide range of drugs and their metabolites, providing comprehensive screening capabilities. Thirdly, urine testing is cost-effective and suitable for high-volume testing, making it practical for workplace screening programs. Furthermore, urine testing is capable of detecting recent drug use, making it suitable for detecting impairment in safety-sensitive industries. Lastly, this testing is less susceptible to adulteration or tampering compared to other sample types, ensuring the integrity and reliability of test results.
Workplaces accounted for the largest market share
Drug screening tests in workplaces are conducted to detect the presence of drugs or alcohol in employees. These tests are typically performed as part of pre-employment screening, random testing, post-accident testing, or reasonable suspicion testing. The aim is to ensure a safe and productive work environment, minimize the risk of accidents and injuries, and deter substance abuse among employees.
North America (the United States and Canada) was the largest market for drug screening
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for drug screening.
Some of the factors driving the North America drug screening market included the growing cases of substance abuse, the increasing number of drug dealers, and the rising black marketing of prescribed drugs. Moreover, drug screening market statistics by IMARC indicate that the growing substance abuse rates in the region are bolstering the need for drug screening. For instance, in February 2023, according to an article published by the Pennsylvania State University, around 63% of adults aged 18 years and above were reported to alcohol consumption in the United States in 2022. Among these, males (66%) had higher alcohol consumption as compared to females (61%). Thus, the large number of alcohol consumers raises the need for drug-testing products and services and is augmenting the market growth in North America. Moreover, the government authorities of North America are mandating drug screening tests in various sectors, which is further catalyzing the market growth. For instance, in May 2023, the United States Department of Transportation regulated the drug testing program by including oral fluid testing to improve safety and reduce the chances of cheating involved with urine drug tests.
(Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.)
March 2024: bioXcelerate, a new and innovative health data science division of Optima Partners Limited, revealed a groundbreaking AI tool, which is set to accelerate the process of identifying and developing new drugs. The tool, known as PleioGraph, can analyze complex medical data 100 times faster than existing state-of-the-art methods used to detect biological networks that explain disease risk and inform drug discovery.
December 2023: Quest Diagnostics, one of the leading providers of diagnostic information services, unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives.
October 2023: In India, Kerala police launched a rapid drug screening system that involves the utilization of a hand-held device, named the SoToxa Mobile Test System, and detects drug usage in 5 minutes.